Clinical Trial Update: Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

This entry reports the completion of a Phase 2 trial evaluating autologous dendritic cell vaccination in patients with Stage II-III HER2-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Autologous dendritic cell vaccine (dendritic cell vaccine)

Snippet

Sponsor: Clinica Universidad de Navarra, Universidad de Navarra | Conditions: Stage II Breast Cancer, Stage III Breast Cancer | Phase 2 | Status: COMPLETED